Full Press Release Details
NEW ORLEANS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Cytokinetics investors should visit us at https://www.claimsfiler.com/cases/nasdaq-cytk or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Cytokinetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 10, 2025, the Company disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for its aficamten product. Then, on May 6, 2025, the Company disclosed that it had held multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy, instead relying on labeling and voluntary education materials.
On this news, the price of Cytokinetics’ shares fell, closing at $33.04 per share on May 7, 2025.
The case is Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
Tags
Securities Litigation